PerspectiveAlzheimer’s Disease

Rapamycin and Alzheimer’s disease: Time for a clinical trial?

See allHide authors and affiliations

Science Translational Medicine  23 Jan 2019:
Vol. 11, Issue 476, eaar4289
DOI: 10.1126/scitranslmed.aar4289

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer’s disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer’s disease. We argue that such clinical trials should be undertaken.

View Full Text